Sanofi Plans Ingredients Unit IPO Within Months: Report
Advertisement
Paris: Sanofi, the French pharmaceutical giant, plans to sell shares in its drug-ingredients division in the next few months, a senior executive said.
The company announced the potential initial public offering in February as Chief Executive Officer Paul Hudson sought to revamp the drugmaker's strategy, focusing on fields such as cancer.
"We'll try to launch it on the market," Sanofi France Chairman Olivier Bogillot said on France Inter radio on Saturday. "We'll do an IPO in the coming months."
"The idea is to create a champion of active ingredients at the European level," Bogillot said.
The unit is combining Sanofi's commercial and development activities with six of its European production sites, including facilities in Frankfurt and Brindisi, Italy.
Read also: Sanofi, GSK begin human trial of coronavirus vaccine candidate
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.